McKesson and CD&R to Acquire Option Care Health for $5.8B

What happened

McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health, a home and alternate site infusion services provider, for $32.05 per share, reflecting an enterprise value of approximately $5.8 billion. The deal extends McKesson's specialty healthcare reach beyond oncology into home infusion, aligning with its strategy to shift toward higher-margin services. However, the latest DeepValue master report rates McKesson as a 'potential sell' due to limited valuation upside and heavy reliance on acquisitions and buybacks to sustain earnings growth. This acquisition fits that pattern of M&A-driven expansion, which has historically included one-time gains and integration risks. With the stock trading near $825, above the report's attractive entry of $720 but below the $880 trim level, investors should assess whether this deal enhances or dilutes long-term value.

Implication

The acquisition of Option Care Health adds a complementary home infusion platform, potentially accelerating specialty revenue growth, but at a premium price that may dilute near-term adjusted EPS. Partnering with CD&R suggests McKesson is sharing financial risk, which could indicate capital constraints or a desire to avoid further leverage amid existing opioid liabilities and ongoing share repurchases. The deal may increase execution risk, as integrating a new business line could distract from the planned medical-surgical spinoff and integration of recent oncology acquisitions. Given the master report's assessment that organic oncology growth is partly acquisition-aided and that adjusted EPS growth leans on buybacks, this move reinforces concerns about growth quality. Until there is evidence of sustained organic profit growth without one-time gains, the stock remains unattractive at current valuation, and a pullback toward $720 would provide a more compelling entry.

Thesis delta

The thesis shift is modest: the Option Care acquisition aligns with McKesson's specialty focus but does not change the fundamental overvaluation and legal risk profile. The partnership with CD&R may signal a more conservative capital allocation approach, but the pattern of inorganic growth persists, reinforcing the 'potential sell' stance.